Nasdaq

Landmark Head-to-Head Study Published in Journal of Periodontology Concludes That BIOLASE REPAIR® Perio Protocol is Superior for Procedure Time and Patient-Reported Outcomes

IRVINE, Calif., July 13, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced data published in the Journal of Periodontology from a clinical trial ...
Nasdaq

Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol

"This exciting study provides further strong evidence that our Waterlase laser and REPAIR® Perio protocol is a safe and effective alternative to surgical treatment for intrabony periodontal defects ...
Seeking Alpha

Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol

The study confirms that BIOLASE's Waterlase REPAIR ® Perio protocol has similar and sustainable clinical outcomes as compared to traditional MIST in treating intrabony defects over the 12-month study ...